Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Equity Ratio: 2014-2025

Historic Equity Ratio for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Sep 2025 value amounting to 0.87.

  • Viridian Therapeutics, Inc.\DE's Equity Ratio fell 4.92% to 0.87 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.87, marking a year-over-year decrease of 4.92%. This contributed to the annual value of 0.90 for FY2024, which is 0.37% up from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Equity Ratio of 0.87 as of Q3 2025, which was down 1.49% from 0.88 recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Equity Ratio ranged from a high of 0.93 in Q3 2022 and a low of 0.84 during Q2 2022.
  • Moreover, its 3-year median value for Equity Ratio was 0.90 (2024), whereas its average is 0.90.
  • Per our database at Business Quant, Viridian Therapeutics, Inc.\DE's Equity Ratio spiked by 44.32% in 2021 and then declined by 7.08% in 2023.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Equity Ratio (Quarterly) stood at 0.92 in 2021, then declined by 1.46% to 0.91 in 2022, then decreased by 0.74% to 0.90 in 2023, then climbed by 0.37% to 0.90 in 2024, then fell by 4.92% to 0.87 in 2025.
  • Its Equity Ratio stands at 0.87 for Q3 2025, versus 0.88 for Q2 2025 and 0.91 for Q1 2025.